Spatial Domain
Spatial Domain (Tier 1)
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__178_C3,5 | Lung | Primary cancer | 3,214 | Immune | 33.5% | 0.89 | 0.33 |
| NSCLC_38242124__IMC__178_C3,6 | Lung | Primary cancer | 1,618 | Immune | 37.0% | 0.88 | 0.36 |
| NSCLC_38242124__IMC__178_C3,7 | Lung | Primary cancer | 3,626 | Tumor/Malignant | 40.8% | 0.76 | 0.57 |
| NSCLC_38242124__IMC__178_C4,1 | Lung | Primary cancer | 3,180 | Immune | 41.6% | 0.78 | 0.51 |
| NSCLC_38242124__IMC__178_C4,11 | Lung | Primary cancer | 1,793 | Stromal | 36.8% | 0.68 | 0.66 |
| NSCLC_38242124__IMC__178_C4,12 | Lung | Primary cancer | 2,303 | Tumor/Malignant | 44.9% | 0.90 | 0.37 |
| NSCLC_38242124__IMC__178_C4,14 | Lung | Primary cancer | 2,709 | Stromal | 27.8% | 0.49 | 0.85 |
| NSCLC_38242124__IMC__178_C4,15 | Lung | Primary cancer | 69 | Other | 81.2% | 0.52 | 0.67 |
| NSCLC_38242124__IMC__178_C4,17 | Lung | Primary cancer | 3,857 | Immune | 63.9% | 0.97 | 0.10 |
| NSCLC_38242124__IMC__178_C4,18 | Lung | Primary cancer | 3,117 | Stromal | 69.5% | 0.99 | 0.08 |
| NSCLC_38242124__IMC__178_C4,2 | Lung | Primary cancer | 3,234 | Tumor/Malignant | 47.2% | 0.90 | 0.35 |
| NSCLC_38242124__IMC__178_C4,3 | Lung | Primary cancer | 841 | Stromal | 59.5% | 0.91 | 0.24 |
| NSCLC_38242124__IMC__178_C4,4 | Lung | Primary cancer | 3,588 | Immune | 39.3% | 0.84 | 0.31 |
| NSCLC_38242124__IMC__178_C4,5 | Lung | Primary cancer | 1,781 | Tumor/Malignant | 34.9% | 0.90 | 0.31 |
| NSCLC_38242124__IMC__178_C4,6 | Lung | Primary cancer | 2,389 | Stromal | 27.6% | 0.76 | 0.51 |
| NSCLC_38242124__IMC__178_C4,7 | Lung | Primary cancer | 1,156 | Stromal | 31.4% | 0.82 | 0.53 |
| NSCLC_38242124__IMC__178_C4,8 | Lung | Primary cancer | 2,624 | Tumor/Malignant | 52.1% | 1.00 | 0.04 |
| NSCLC_38242124__IMC__178_C4,9 | Lung | Primary cancer | 3,608 | Stromal | 26.9% | 0.45 | 0.91 |
| NSCLC_38242124__IMC__178_C5,1 | Lung | Primary cancer | 2,844 | Stromal | 30.1% | 0.72 | 0.60 |
| NSCLC_38242124__IMC__178_C5,10 | Lung | Primary cancer | 3,113 | Tumor/Malignant | 49.0% | 0.96 | 0.14 |
Spatial Domain (Tier 2)
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__178_C3,5 | Lung | Primary cancer | 3,214 | Myeloid | 27.5% | 0.52 | 0.97 |
| NSCLC_38242124__IMC__178_C3,6 | Lung | Primary cancer | 1,618 | Myeloid | 29.9% | 0.89 | 0.31 |
| NSCLC_38242124__IMC__178_C3,7 | Lung | Primary cancer | 3,626 | Tumor/Malignant | 36.0% | 0.92 | 0.30 |
| NSCLC_38242124__IMC__178_C4,1 | Lung | Primary cancer | 3,180 | Myeloid | 36.4% | 0.89 | 0.32 |
| NSCLC_38242124__IMC__178_C4,11 | Lung | Primary cancer | 1,793 | Stromal | 27.4% | 0.54 | 0.79 |
| NSCLC_38242124__IMC__178_C4,12 | Lung | Primary cancer | 2,303 | Tumor/Malignant | 42.1% | 0.92 | 0.35 |
| NSCLC_38242124__IMC__178_C4,14 | Lung | Primary cancer | 2,709 | Stromal | 26.3% | 0.90 | 0.28 |
| NSCLC_38242124__IMC__178_C4,15 | Lung | Primary cancer | 69 | Other | 81.2% | 0.52 | 0.67 |
| NSCLC_38242124__IMC__178_C4,17 | Lung | Primary cancer | 3,857 | Lymphoid | 54.7% | 0.98 | 0.06 |
| NSCLC_38242124__IMC__178_C4,18 | Lung | Primary cancer | 3,117 | Stromal | 69.5% | 0.99 | 0.08 |
| NSCLC_38242124__IMC__178_C4,2 | Lung | Primary cancer | 3,234 | Tumor/Malignant | 40.3% | 0.93 | 0.28 |
| NSCLC_38242124__IMC__178_C4,3 | Lung | Primary cancer | 841 | Stromal | 35.3% | 0.98 | 0.11 |
| NSCLC_38242124__IMC__178_C4,4 | Lung | Primary cancer | 3,588 | Tumor/Malignant | 31.8% | 0.97 | 0.13 |
| NSCLC_38242124__IMC__178_C4,5 | Lung | Primary cancer | 1,781 | Tumor/Malignant | 34.5% | 0.91 | 0.30 |
| NSCLC_38242124__IMC__178_C4,6 | Lung | Primary cancer | 2,389 | Stromal | 28.1% | 0.45 | 0.94 |
| NSCLC_38242124__IMC__178_C4,7 | Lung | Primary cancer | 1,156 | Stromal | 25.3% | 0.55 | 0.89 |
| NSCLC_38242124__IMC__178_C4,8 | Lung | Primary cancer | 2,624 | Tumor/Malignant | 64.2% | 0.96 | 0.13 |
| NSCLC_38242124__IMC__178_C4,9 | Lung | Primary cancer | 3,608 | Stromal | 24.1% | 0.51 | 0.95 |
| NSCLC_38242124__IMC__178_C5,1 | Lung | Primary cancer | 2,844 | Tumor/Malignant | 27.4% | 0.96 | 0.18 |
| NSCLC_38242124__IMC__178_C5,10 | Lung | Primary cancer | 3,113 | Tumor/Malignant | 48.6% | 0.97 | 0.13 |
Spatial Domain (Tier 3)
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__178_C3,5 | Lung | Primary cancer | 3,214 | Myeloid cell, unspecified | 22.3% | 0.68 | 0.84 |
| NSCLC_38242124__IMC__178_C3,6 | Lung | Primary cancer | 1,618 | Myeloid cell, unspecified | 34.6% | 0.88 | 0.38 |
| NSCLC_38242124__IMC__178_C3,7 | Lung | Primary cancer | 3,626 | Tumor/Malignant cell | 40.3% | 0.89 | 0.35 |
| NSCLC_38242124__IMC__178_C4,1 | Lung | Primary cancer | 3,180 | Myeloid cell, unspecified | 49.8% | 0.86 | 0.41 |
| NSCLC_38242124__IMC__178_C4,11 | Lung | Primary cancer | 1,793 | Fibroblast | 31.6% | 0.56 | 0.84 |
| NSCLC_38242124__IMC__178_C4,12 | Lung | Primary cancer | 2,303 | Tumor/Malignant cell | 48.3% | 0.88 | 0.41 |
| NSCLC_38242124__IMC__178_C4,14 | Lung | Primary cancer | 2,709 | Fibroblast | 23.3% | 0.86 | 0.38 |
| NSCLC_38242124__IMC__178_C4,15 | Lung | Primary cancer | 69 | Other | 81.2% | 0.52 | 0.78 |
| NSCLC_38242124__IMC__178_C4,17 | Lung | Primary cancer | 3,857 | B cell | 49.2% | 0.94 | 0.15 |
| NSCLC_38242124__IMC__178_C4,18 | Lung | Primary cancer | 3,117 | Fibroblast | 69.5% | 0.99 | 0.08 |
| NSCLC_38242124__IMC__178_C4,2 | Lung | Primary cancer | 3,234 | Tumor/Malignant cell | 45.3% | 0.91 | 0.33 |
| NSCLC_38242124__IMC__178_C4,3 | Lung | Primary cancer | 841 | Endothelial cell | 51.0% | 0.72 | 0.51 |
| NSCLC_38242124__IMC__178_C4,4 | Lung | Primary cancer | 3,588 | Granulocyte | 39.2% | 0.84 | 0.30 |
| NSCLC_38242124__IMC__178_C4,5 | Lung | Primary cancer | 1,781 | Tumor/Malignant cell | 34.8% | 0.90 | 0.31 |
| NSCLC_38242124__IMC__178_C4,6 | Lung | Primary cancer | 2,389 | Fibroblast | 25.1% | 0.61 | 0.76 |
| NSCLC_38242124__IMC__178_C4,7 | Lung | Primary cancer | 1,156 | Fibroblast | 31.6% | 0.38 | 0.94 |
| NSCLC_38242124__IMC__178_C4,8 | Lung | Primary cancer | 2,624 | Tumor/Malignant cell | 61.0% | 0.97 | 0.11 |
| NSCLC_38242124__IMC__178_C4,9 | Lung | Primary cancer | 3,608 | Fibroblast | 22.9% | 0.75 | 0.61 |
| NSCLC_38242124__IMC__178_C5,1 | Lung | Primary cancer | 2,844 | Tumor/Malignant cell | 27.7% | 0.96 | 0.19 |
| NSCLC_38242124__IMC__178_C5,10 | Lung | Primary cancer | 3,113 | Tumor/Malignant cell | 50.0% | 0.96 | 0.16 |